Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 02, 2021 7:37pm
90 Views
Post# 33111688

RE:RE:RE:Capital Market and Proxy Notes

RE:RE:RE:Capital Market and Proxy Notes

If Life Sci is the cornerstone of the strat then it doesn't look like retail investors is going to be a big part of that. Looks like their focus is to the professional investor sector. The problem is the company has outlined it's strat now, it ain't going to change. So do you accept that?


scarlet1967 wrote:

First of all I would like to praise wino for his efforts, honoring the company’s request I am going to bring up few things without discussing specifics also I apologies for an element of negativity in my points I guess I have my reasons for not being more positive.
1-Apart from the life science approach it wasn’t any details in the conversation about plans to attract retail investors and as mentioned earlier many times the retail segment has grown significantly specifically in the last couple of years therefore many companies have shifted their marketing strategies targeting the retail investors more actively/on a continues basis.
2-The company seems to think the board’s composition as it stand now is almost ideal my concern is this board had long enough time to educate/motivate institutions, retail segment etc. which hasn’t been successful to date and it seems like they are happy to keep implementing same strategies going forward and it concerns me because they still think their failing strategy is the right one and needs more time.
3-I don’t think they own enough shares and it is important as if they each had a significant holding they would be much more motivated/engaged to utilize whatever tools available to support the valuation, often companies with higher insider ownership than THTX’s 1.2% have more proactive/protective leadership and I can name many companies with much higher insider ownership but very few with less than THTX. It’s just part of human nature to protect your interest first before others.
4-As wino pointed out time is essence specifically for a company which has been falling behind the competition with their marketing and I just don’t sense the urgency needed from the company to deal with many issues discussed by us, again if one is falling behind in a race you won’t catch up by going at the same speed as others, for instance how long does it take to upgrade the  website remember if I recommend this company to a friend as there isn’t many coverage/information out there that person probably search the internet first they will come  across this MB and stocktwits with few followers compared to the piers and next thing they will do is to look at their website therefore having an appealing website is not only is essential but their very first point of sale, often that point of sale has very narrow window so after a short period of time that potential future investor will decide to keep researching or move on. That is why it is a must/start to have the website setup in a way that everyone from educated investors to average joe type understand and is impressed by and it should have been done long ago.
5-As per the IR communicating with shareholders has improved I am afraid that hasn’t been the case at all, try to send few emails to Leah with legit enquiries and see how many of those she choose to respond to even if the enquiry is not legit and she can’t address it because of strategic reason/none public information a friendly IR person would respond back and explain the reason why they can’t discuss it.
6-Overall it doesn’t look like there will be significant changes, yes it seems the plan is to try harder with their current strategies which after many years seems to have not been successful which is hard to digest in the middle of the longest bull market in the history. 
 


<< Previous
Bullboard Posts
Next >>